Regeneron Pharmaceuticals (REGN) Net Margin (2009 - 2026)

Regeneron Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 30.23% for Q2 2026.

• In Q2 2026, Net Margin fell 763.0% year-over-year to 30.23%; the TTM figure through Jun 2026 stood at 27.86% (down 350.0% YoY), while the FY2025 annual figure was 31.41%, up 34.0% from the prior year.
• Net Margin for Q2 2026 stood at 30.23%, up from 20.17% in the prior quarter.
• The five-year high for Net Margin was 1947.0% in Q1 2022, with the low at 20.17% in Q1 2026.
• The 5-year median for Net Margin is 30.44% (2026), against an average of 202.12%.
• The sharpest annual moves came in 2022 and 2023: Net Margin surged 190290 bps in 2022, then slumped 192114 bps in 2023.
• Regeneron Pharmaceuticals' Net Margin stood at 1197.1% in 2022, then tumbled by 97 bps to 33.77% in 2023, then slipped by 28 bps to 24.22% in 2024, then retreated by 10 bps to 21.74% in 2025, then soared by 39 bps to 30.23% in 2026.
• Business Quant data shows REGN's Net Margin at 30.23% in Q2 2026, 20.17% in Q1 2026, and 21.74% in Q4 2025.